Medizin - Open Access LMU - Teil 16/22

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer


Listen Later

Purpose: Previous phase II studies have indicated a greatly reduced hematotoxicity of docetaxel-based regimens administered on weekly schedules. The present trial was initiated to randomly compare the toxicity and efficacy of weekly docetaxel versus its standard 3-weekly application. Methods: Patients previously untreated with chemotherapy for metastatic disease were recruited. Patients aged >60 years or with a Karnofsky Perfomance Status (KPS) of 60-80% were eligible for the D2 study. Patients were randomized to receive docetaxel either on a 3-weekly {[}75 mg/m(2) every 3 weeks (q3w)] or on a weekly (30 mg/m(2) on days 1, 8, and 15; q4w) schedule. Treatment was continued until a maximum of 8 cycles, unacceptable toxicity, or disease progression. All patients received standard corticosteroid prophylaxis. Results: Since statistical significance for the primary endpoint (toxicity) was achieved in the interim analysis, the study was closed according to the study protocol (102 of 162 patients). Compared to the standard arm, leukopenia >= grade 3 was a rare event in the weekly arm of the D2 study (per-patient analysis: 4.2% q1w vs. 51.9% q3w; p < 0.0001). No difference was observed between the 2 schedules regarding the occurrence of anemia or thrombocytopenia. With regard to non-hematological toxicity, there was a higher incidence of skin/nail and hepatological toxicity with the weekly schedule, whereas neurotoxicity was observed more often in the standard arm. The rate of omitted doses was significantly increased in the weekly arm (8.6% q1w vs. 0% q3w). The overall response rate was 22.9% in the weekly arm compared to 42.6% in the standard arm (p = 0.039). Time to progression was 5.4 (q1w) versus 6.3 (q3w) months (p = 0.91), and overall survival was 22.7 (q1w) versus 15.8 (q3w) months (p = 0.24). Conclusion: The present data support the feasibility of both weekly and 3-weekly application of docetaxel. As expected, severe leukopenia seems avoidable in weekly scheduled single-agent docetaxel and may serve as an important treatment option, particularly in elderly patients and patients with a reduced performance status. Copyright (C) 2011 S. Karger AG, Basel
...more
View all episodesView all episodes
Download on the App Store

Medizin - Open Access LMU - Teil 16/22By Ludwig-Maximilians-Universität München


More shows like Medizin - Open Access LMU - Teil 16/22

View all
Geld und Leben - Ringvorlesung (WiSe 2009-2010) by Ludwig-Maximilians-Universität München

Geld und Leben - Ringvorlesung (WiSe 2009-2010)

0 Listeners

MCMP – Mathematical Philosophy (Archive 2011/12) by MCMP Team

MCMP – Mathematical Philosophy (Archive 2011/12)

6 Listeners

Hegel lectures by Robert Brandom, LMU Munich by Robert Brandom, Axel Hutter

Hegel lectures by Robert Brandom, LMU Munich

6 Listeners

LMU Statistik I für Studierende der Wirtschaftswissenschaften by PD Dr. Christian Heumann

LMU Statistik I für Studierende der Wirtschaftswissenschaften

0 Listeners

Institut für Produktionswirtschaft und Controlling (LMU) by Prof. Dr. Dr. h.c. Hans-Ulrich Küpper

Institut für Produktionswirtschaft und Controlling (LMU)

0 Listeners

Center for Advanced Studies (CAS) Cutting Edge - SD by Center for Advanced Studies (CAS)

Center for Advanced Studies (CAS) Cutting Edge - SD

0 Listeners

LMU Rechtsphilosophie by Prof. Dr. jur. Dr. jur. h.c. mult. Bernd Schünemann

LMU Rechtsphilosophie

0 Listeners

MCMP – Philosophy of Science by MCMP Team

MCMP – Philosophy of Science

1 Listeners

LMU Physik 2 für Chemiker (PN2) SS2016 by Prof. Dr. Jan Lipfert

LMU Physik 2 für Chemiker (PN2) SS2016

0 Listeners

Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 05/06 by Ludwig-Maximilians-Universität München

Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 05/06

0 Listeners